Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

1.

Ensalutamide (Xtandi) for prostate cancer.

[No authors listed]

Med Lett Drugs Ther. 2013 Mar 4;55(1411):20. No abstract available.

PMID:
23467121
[PubMed - indexed for MEDLINE]
2.

The role of enzalutamide in the treatment of castration-resistant prostate cancer.

Rawlinson A, Mohammed A, Miller M, Kunkler R.

Future Oncol. 2012 Sep;8(9):1073-81. doi: 10.2217/fon.12.99. Review.

PMID:
23030482
[PubMed - indexed for MEDLINE]
3.

Enzalutamide for the treatment of castration-resistant prostate cancer.

Ha YS, Goodin S, DiPaola RS, Kim IY.

Drugs Today (Barc). 2013 Jan;49(1):7-13. doi: 10.1358/dot.2013.49.1.1910724. Review.

PMID:
23362491
[PubMed - indexed for MEDLINE]
4.

Revisiting the ultimate target of treatment for prostate cancer.

Dahut WL, Madan RA.

Lancet. 2010 Apr 24;375(9724):1409-10. doi: 10.1016/S0140-6736(10)60400-X. Epub 2010 Apr 14. No abstract available.

PMID:
20398924
[PubMed - indexed for MEDLINE]
5.

[The molecular mechanisms of resistance to androgen deprivation therapy in prostate cancer].

Kosaka T, Oya M.

Nihon Rinsho. 2012 Nov;70 Suppl 8:353-9. Japanese. No abstract available.

PMID:
23513865
[PubMed - indexed for MEDLINE]
6.

Landmarks in hormonal therapy for prostate cancer.

Hammerer P, Madersbacher S.

BJU Int. 2012 Oct;110 Suppl 1:23-9. doi: 10.1111/j.1464-410X.2012.11431.x. Review.

PMID:
23046037
[PubMed - indexed for MEDLINE]
7.

The evolution of antiandrogens: MDV3100 comes of age.

Dumas L, Payne H, Chowdhury S.

Expert Rev Anticancer Ther. 2012 Feb;12(2):131-3. doi: 10.1586/era.11.210. No abstract available.

PMID:
22316360
[PubMed - indexed for MEDLINE]
8.

Enzalutamide for the treatment of prostate cancer.

Pal SK, Stein CA, Sartor O.

Expert Opin Pharmacother. 2013 Apr;14(5):679-85. doi: 10.1517/14656566.2013.775251. Epub 2013 Feb 27. Review.

PMID:
23441761
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

The androgen receptor, androgen synthesis, and new designer antiandrogens for metastatic castration-resistant prostate cancer: teaching old dogs new tricks.

Lieberman R.

Am J Ther. 2013 Mar-Apr;20(2):128-31. doi: 10.1097/MJT.0b013e3182857f8e. No abstract available.

PMID:
23466618
[PubMed - indexed for MEDLINE]
10.

[Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].

Pinto F, Calarco A, Totaro A, Sacco E, Volpe A, Racioppi M, D'Addessi A, Bassi PF.

Urologia. 2010 Apr-May;77(2):71-83. Review. Italian.

PMID:
20890863
[PubMed - indexed for MEDLINE]
11.

[How to treat prostatic cancer?].

Lundberg M.

Lakartidningen. 2005 Aug 8-21;102(32-33):2244. Swedish. No abstract available.

PMID:
16145890
[PubMed - indexed for MEDLINE]
12.

Targeting the androgen receptor.

Friedlander TW, Ryan CJ.

Urol Clin North Am. 2012 Nov;39(4):453-64. doi: 10.1016/j.ucl.2012.07.003. Review.

PMID:
23084523
[PubMed - indexed for MEDLINE]
13.

Beyond castration and chemotherapy: novel approaches to targeting androgen-driven pathways.

Pal SK, Twardowski P, Josephson DY.

Maturitas. 2009 Oct 20;64(2):61-6. doi: 10.1016/j.maturitas.2009.08.004. Epub 2009 Sep 5. Review.

PMID:
19733987
[PubMed - indexed for MEDLINE]
14.

Degarelix (firmagon) for prostate cancer.

[No authors listed]

Med Lett Drugs Ther. 2009 Oct 19;51(1323):82-3. Review. No abstract available.

PMID:
19838145
[PubMed - indexed for MEDLINE]
15.

Development of androgen receptor antagonists with promising activity in castration-resistant prostate cancer.

Shen HC, Balk SP.

Cancer Cell. 2009 Jun 2;15(6):461-3. doi: 10.1016/j.ccr.2009.05.005.

PMID:
19477425
[PubMed - indexed for MEDLINE]
Free Article
16.

Drug development. New way to target hormone receptor thwarts prostate cancer.

Kaiser J.

Science. 2009 Apr 10;324(5924):165. doi: 10.1126/science.324.5924.165a. No abstract available.

PMID:
19359556
[PubMed - indexed for MEDLINE]
17.

Triple-acting drug boosts prostate cancer survival.

[No authors listed]

Cancer Discov. 2011 Dec;1(7):OF1. doi: 10.1158/2159-8290.CD-NB111711OL-09. Epub 2011 Nov 17.

PMID:
22586690
[PubMed - indexed for MEDLINE]
18.

The role of intermittent androgen deprivation in prostate cancer.

Boccon-Gibod L, Hammerer P, Madersbacher S, Mottet N, Prayer-Galetti T, Tunn U.

BJU Int. 2007 Oct;100(4):738-43. Epub 2007 Jul 23. Review. No abstract available.

PMID:
17662079
[PubMed - indexed for MEDLINE]
19.

[Antiandrogen in prostate cancer].

Maeda O, Usami M.

Nihon Rinsho. 2002 Dec;60 Suppl 11:188-92. Review. Japanese. No abstract available.

PMID:
12599569
[PubMed - indexed for MEDLINE]
20.

Anti-androgen monotherapy for metastatic prostate cancer.

Attard G.

Lancet Oncol. 2014 May;15(6):543-4. doi: 10.1016/S1470-2045(14)70159-7. Epub 2014 Apr 14. No abstract available.

PMID:
24739898
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk